抗结核药物联合使用对耐多药结核分枝杆菌抗菌效力的研究

摘要/Abstract

摘要： 目的研究常用抗结核药物与其它抗结核药物联合使用对多耐药结核菌 (MDR-MTB)的抗菌效力。方法按照部分耐药浓度 (FIC)方法测定 (MDR-MTB)单独用药及联合用药时标准结核分枝杆菌的最低抑菌浓度 (MIC)，临床分离株的最低抑菌浓度 (MICs)，按照FIC公式，计算其是否有协同作用。结果 INH、RFP、EMB、CAM和INH、RFP、PZA、OFLX组合对13株临床分离的MDR-MTB的FIC＜05,有协同作用。结论本体外实验证实，INH、RFP、EMB、CAM和INH、RFP、PZA、OFLX两种组合形式对实验所用的13株MDR-MTB有协同作用。

关键词: 分枝杆菌,结核, 药物耐受性, 部分抑菌浓度

Abstract: Objective To explore the role of antituberculous drugs in common use and in combination against Multidrug-resistant Mycobacterium tuberculosis with another antituberculous drugs.Methods To determine MIC and MICs each single drug and in combination to different Multidrug-resistant M.tuberculosis strains,according to FIC formula,count out the synergetic activitives.Results FIC of in combination of INH,RFP,EMB,CAM and INH,RFP,PZA,OFLX are less than 0 5.Conculusion In vitro,constitution of INH,RFP,EMB,CAM and INH,RFP,PZA,OFLX have been confirmed that have synergetic effect to multidrug-resistant M.tuberculosis.

Key words: M.tuberculosis, Drug resistant, Fractional inhibition concentration (FIC)

马海战,陈峥,. 抗结核药物联合使用对耐多药结核分枝杆菌抗菌效力的研究[J]. 中国防痨杂志, 2000, 22(3): 157-160.

MA Hai-zhan,CHEN Zheng.. A research on effect of anti-germ for Multiresistant M.tuberculosis with antituberculous drugs in combination[J]. Chinese Journal of Antituberculosis, 2000, 22(3): 157-160.

参考文献

[1] Person ML, Jereb JA, Frieden TR, et al. Nosocomical transmission of multidrug-resistant mycobacterium tuberculosis. A risk to patients and health care workers [J].Ann Intern Med, 1992,117：191-196
[2] Gobld M, Iseman MD, Madsen LA, et al. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin [J]. N Engl J Med.1993,328:527-532.
[3] WOH Global TB Programme. WHO Report on the Tuberculosis Epidemic 1996[R].Geneva.1996.
[4] Leonid H. Qualitative and quantitative drug-susceptibility tests mycobacteriology [J]. Am Rev Respir Dis,1998,137：1217-1222.
[5] Dickinson J M. Aber VR, Mitchiaon A. Bactericial activity of strepto-mycin, isoniazid, rifampin, ethambutol. and pyrazinamide alone and in combination against Mycobacterium tuberculosis [J]. Am Rev Respir DIS, 1997,116:627-635.
[6] Nicola A. Carione Acocella, Anna Maria Cuffini，Martina Fcxno-piz-zoglio. Killing of macrophage-ingested Mycobacteria by rifampicin 9 pyrazinamide,and pyrazinoic acid alone and in combination [J]. Am Rev Respir Dis, 1985,132：1274-1277.
[7] Stephen JC，Jon RB. Synapstic activities of clarithrranycin and antitu-berculos drugs against multidrug-resistant Mycobacterium tuberculosis [J]. Antimicrobial Agents and Chemotherapy,1995,1542-1545.
[8] 罗永艾,王宠林，黄中臣，等.复治肺结核病人痰菌耐药不均一性研究[J]，中国防痨杂志,1991,13(4)：166-168.
[9] Alfred JC,Mary HM. Inhibition of tubercle bacilli in cultured human macrophages by chloroquine used alone and in combination with strep-tomycin, isoniazid, pyrazinamide, and two metabolites of vitamin D₃ [J] .Antimicrobial Agents ang Chemotherapy.1990,2217-2222.
[10] 宋文虎，肖成志,宋礼章，主编.结核病学进展[M].北京：光明日报出版社，1995,95-113.
[11] Alferd JC,Max SF,Mary HM. L-25(OH)₂ Vitamin D₃ synergizes with pyrazinamide to kill tubercle bacilli in cultured human macrophages. [J].Am Rev Respir Dis,1989,139:549-552.
[12] Leonid H, Pamela L. Pyrazinmide steering activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations [J]. Am Rev Respir Dis,1992,145:1223-1225.
[13] Alfred JC, Elise JR. Comparative abilities of various metabolites of vitamin D to protect human macrophages against tubecler bacilli [J].Journal of Leukocyte Biology,47：545-550

[1]	周银发,张山鹰,戴志松,陈代权,李卫林,赵永,林淑芳. 福建省耐药肺结核高危人群利福平耐药情况及其影响因素分析[J]. 中国防痨杂志, 2020, 42(4): 339-344.
[2]	张蓝月,耿艺漫,贾红彦,肖婧,李自慧,潘丽萍,孙义成,张宗德. 耻垢分枝杆菌新型毒素-抗毒素系统MSMEG_3435-3436基因功能的初步研究[J]. 中国防痨杂志, 2020, 42(2): 133-142.
[3]	吴雪琼张俊仙. 合理应用药物敏感性试验提高耐多药结核病诊断率[J]. 中国防痨杂志, 2017, 39(3): 222-225.
[4]	缪梓萍,郑锦雷,柳正卫,何海波,何铁牛,刘北斗. 复治肺结核耐药性与用药史关系研究[J]. 中国防痨杂志, 2008, 30(4): 304-307.
[5]	李洪敏,梁建琴,王巍,陈红兵,苗青,张霞,. 结核分枝杆菌Km基因突变与耐卡那霉素药物的研究[J]. 中国防痨杂志, 2008, 30(1): 37-39.
[6]	缪梓萍,李群,何海波,柳正卫,杨石波,郑锦雷,刘北斗. 浙江省耐药结核病现状及趋势研究[J]. 中国防痨杂志, 2007, 29(3): 215-218.
[7]	高凌玉,张健源,李传友,周建琴,游雪甫,王振,汪月,孙承航,. 康乐霉素A体外抗结核活性的初步研究[J]. 中国防痨杂志, 2007, 29(2): 160-162.
[8]	赵黎黎,马海战,曹文利,李文杰,张培元,张进平,孙桂芝,. 利福喷汀治疗耐利福平肺结核80例临床疗效观察[J]. 中国防痨杂志, 2006, 28(4): 244-246.
[9]	吴龙章,黄洁玲,张院良,蔡杏珊,关平. 广东省广州市2001—2004年分枝杆菌初步菌种鉴定与药物敏感性试验结果分析[J]. 中国防痨杂志, 2006, 28(3): 170-173.
[10]	杜长梅,王国斌,徐吉英,王国杰,胡惠义,甄新安,李爱华,孙占强,闫国蕊,. 河南省第二轮结核病耐药监测及耐药趋势研究[J]. 中国防痨杂志, 2006, 28(2): 95-100.
[11]	罗一鲁,刘志辉,罗春明,. 1994—2003年广州老城区门诊病人耐药结核病流行状况分析[J]. 中国防痨杂志, 2005, 27(4): 247-250.
[12]	高春荣,袁东运,徐立江,. 含阿米卡星及左氧氟沙星方案治疗耐多药肺结核近期疗效观察[J]. 中国防痨杂志, 2004, 26(3): 165-167.
[13]	安慧茹,王巍,李洪敏,梁建琴,刘真,李素梅,何珂,. 结核分枝杆菌耐喹诺酮临床分离株gyrA基因突变的研究[J]. 中国防痨杂志, 2004, 26(3): 129-132.
[14]	吴风霞,李慧灵,王鑫君,. 结核分枝杆菌L型检测的临床意义[J]. 中国防痨杂志, 2004, 26(2): 107-109.
[15]	刘日宏,哈斯,蔚景荣,韩新华,王俊英,李玉才,. 内蒙古乌兰察布盟结核分枝杆菌耐药性监测研究[J]. 中国防痨杂志, 2004, 26(2): 92-94.